Hepatocellular Carcinoma Rupture after Introducing Lenvatinib: An Autopsy Case Report

  • Kohya Risako
    Department of Gastroenterology and Hepatology, Hakodate Municipal Hospital, Japan
  • Sugiura Ryo
    Department of Gastroenterology and Hepatology, Hakodate Municipal Hospital, Japan Department of Gastroenterology and Hepatology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Japan
  • Yamamoto Yoshiya
    Department of Gastroenterology and Hepatology, Hakodate Municipal Hospital, Japan
  • Naruse Hirohito
    Department of Gastroenterology and Hepatology, Hakodate Municipal Hospital, Japan
  • Hatanaka Kazuteru
    Department of Gastroenterology and Hepatology, Hakodate Municipal Hospital, Japan
  • Kinoshita Kenji
    Department of Gastroenterology and Hepatology, Hakodate Municipal Hospital, Japan
  • Abiko Satoshi
    Department of Gastroenterology and Hepatology, Hakodate Municipal Hospital, Japan
  • Miyamoto Shuichi
    Department of Gastroenterology and Hepatology, Hakodate Municipal Hospital, Japan
  • Suzuki Kazuharu
    Department of Gastroenterology and Hepatology, Hakodate Municipal Hospital, Japan
  • Kushibiki Hanae
    Department of Pathology, Hakodate Municipal Hospital, Japan
  • Munakata Satoru
    Department of Pathology, Hakodate Municipal Hospital, Japan
  • Shimoyama Norihiko
    Department of Pathology, Hakodate Municipal Hospital, Japan

Search this article

Abstract

<p>Hepatocellular carcinoma (HCC) hemorrhaging/rupture is a rare adverse effect of lenvatinib, and only limited pathological examinations have been reported. This report presents the case of a 69-year-old man who suffered from cardiac arrest and died 7 days after starting lenvatinib treatment for HCC, with an autopsy subsequently performed. Crack and coagulated blood were observed in the largest tumor. Pathologically, the hemorrhaging area was scattered in nearly all of the HCC lesions, regardless of tumor differentiation. This pathological feature is unusual in normal HCC. Thus, it is believed to have been the effect of lenvatinib. </p>

Journal

  • Internal Medicine

    Internal Medicine 62 (7), 995-998, 2023-04-01

    The Japanese Society of Internal Medicine

Citations (1)*help

See more

References(10)*help

See more

Details 詳細情報について

Report a problem

Back to top